A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisanie świadomej zgody na uczestnictwo w badaniu
- •Wiek 18-70 lat w momencie podpisania zgody
- •Dobry stan ogólny zdrowia (ocena ECOG: 0 lub 1)
- •Rak piersi triple-negative w stadium IIA-IIIIC, bez przerzutów, po zabiegu chirurgicznym
- •Potwierdzenie w badaniu histologicznym: ujemne markery HER2, receptorów estrogenowych i progesteronowych
- •Wykonanie zabiegu: oszczędzającego pierś lub całkowitego usunięcia piersi
- •Prawidłowe wyniki badań laboratoryjnych (liczba krwinek, wątroby i nerek) z ostatnich 28 dni
- •Dla kobiet w wieku rozrodczym: stosowanie antykoncepcji przez co najmniej 5 miesięcy po zakończeniu leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- July 16, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, China
Trial contact
Zhimin Shao, MD,PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.